

**Amendments to the Claims**

This listing of claims replaces all previous versions and listings of claims.

**Listing of Claims:**

23. (previously presented) An isolated protein comprising amino acid residues 1 to 353 of SEQ ID NO:11.

24. (previously presented) The protein of claim 23 which comprises a heterologous polypeptide sequence.

25. (previously presented) A composition comprising the protein of claim 23 and a pharmaceutically acceptable carrier.

26. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 23 by a cell; and
- (b) recovering said protein.

27. (previously presented) An isolated protein comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

28. (previously presented) The protein of claim 27 which comprises a heterologous polypeptide sequence.

29. (previously presented) A composition comprising the protein of claim 27 and a pharmaceutically acceptable carrier.

30. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 27 by a cell; and
- (b) recovering said protein.

31. (currently amended) An isolated protein comprising a ~~contiguous amino acid sequence which is~~ first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 353 of SEQ ID NO: 11, wherein said first polypeptide binds hyaluronan.

32. (currently amended) The isolated protein of claim 31 wherein said ~~amino acid sequence~~ first polypeptide is at least 95% identical to said second polypeptide ~~amino acid residues 1 to 353 of SEQ ID NO:11.~~

33. (previously presented) The protein of claim 31 which comprises a heterologous polypeptide sequence.

34. (previously presented) A composition comprising the protein of claim 31 and a pharmaceutically acceptable carrier.

35. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 31 by a cell; and
- (b) recovering said protein.

36. (currently amended) An isolated protein comprising a ~~contiguous amino acid sequence which is~~ first polypeptide at least 90% identical to a second polypeptide consisting of the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502, wherein said first polypeptide binds hyaluronan.

37. (currently amended) The isolated protein of claim 36 wherein said ~~amino acid sequence~~ first polypeptide is at least 95% identical to said second polypeptide ~~the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.~~

38. (previously presented) The protein of claim 36 which comprises a heterologous polypeptide sequence.

39. (previously presented) A composition comprising the protein of claim 43 and a pharmaceutically acceptable carrier.

40. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 36 by a cell; and
- (b) recovering said protein.

41. (currently amended) An isolated protein ~~comprising~~ consisting of at least 10 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.

42. (currently amended) The isolated protein of claim 41 which ~~comprises~~ consists of at least 20 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.

43. (currently amended) The isolated protein of claim 41 which ~~comprises~~ consists of at least 30 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.

44. (currently amended) The isolated protein of claim 41 which ~~comprises~~ consists of at least 50 contiguous amino acid residues of amino acid residues 1 to 353 of SEQ ID NO:11.

45. (previously presented) The protein of claim 41 which comprises a heterologous polypeptide sequence.

46. (previously presented) A composition comprising the protein of claim 41 and a pharmaceutically acceptable carrier.

47. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 41 by a cell; and
- (b) recovering said protein.

48. (currently amended) An isolated protein ~~comprising~~ consisting of at least 10 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

49. (currently amended) The isolated protein of claim 48 which ~~comprises~~ consists of at least 20 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

50. (currently amended) The isolated protein of claim 48 which ~~comprises~~ consists of at least 30 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

51. (currently amended) The isolated protein of claim 48 which ~~comprises~~ consists of at least 50 contiguous amino acid residues of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 203502.

52. (previously presented) The protein of claim 48 which comprises a heterologous polypeptide sequence.

53. (previously presented) A composition comprising the protein of claim 48 and pharmaceutically acceptable carrier.

54. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 48 by a cell; and
- (b) recovering said protein.

55. (currently amended) An isolated polypeptide ~~protein~~ ~~comprising~~ consisting of a contiguous amino acid sequence selected from the group consisting of:

- (a) amino acids 7 to 15 of SEQ ID NO:11;
- (b) amino acids 22 to 30 of SEQ ID NO:11;
- (c) amino acids 31 to 39 of SEQ ID NO:11;
- (d) amino acids 61 to 69 of SEQ ID NO:11;
- (e) amino acids 70 to 78 of SEQ ID NO:11;
- (f) amino acids 93 to 101 of SEQ ID NO:11;
- (g) amino acids 107 to 115 of SEQ ID NO:11;
- (h) amino acids 120 to 128 of SEQ ID NO:11;
- (i) amino acids 135 to 143 of SEQ ID NO:11;
- (j) amino acids 148 to 156 of SEQ ID NO:11;
- (k) amino acids 193 to 201 of SEQ ID NO:11; and
- (l) amino acids 229 to 237 of SEQ ID NO:11.

56. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (a).

57. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (b).

58. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (c).

59. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (d).

60. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (e).

61. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~ wherein said amino acid sequence is (f).

62. (currently amended) The polypeptide ~~protein~~ of claim 55 ~~which comprises~~

wherein said amino acid sequence is (g).

63. (currently amended) The polypeptide protein of claim 55 ~~which comprises~~  
wherein said amino acid sequence is (h).

64. (currently amended) The polypeptide protein of claim 55 ~~which comprises~~  
wherein said amino acid sequence is (i).

65. (currently amended) The polypeptide protein of claim 55 ~~which comprises~~  
wherein said amino acid sequence is (j).

66. (currently amended) The polypeptide protein of claim 55 ~~which comprises~~  
wherein said amino acid sequence is (k).

67. (canceled)

68. (currently amended) The polypeptide protein of claim 55 ~~which comprises~~  
wherein said amino acid sequence is (l).

69. (currently amended) The polypeptide protein of claim 55, wherein said  
polypeptide is fused to which comprises a heterologous polypeptide sequence.

70. (currently amended) A composition comprising the polypeptide protein of  
claim 55 and a pharmaceutically acceptable carrier.

71. (currently amended) An isolated polypeptide protein produced by the method  
comprising:

- (a) expressing the polypeptide protein of claim 55 by a cell; and
- (b) recovering said polypeptide protein.

72. (currently amended) An isolated polypeptide protein comprising consisting of  
a contiguous amino acid sequence selected from the group consisting of:

- (a) amino acids 51 to 100 of SEQ ID NO:11;
- (b) amino acids 105 to 150 of SEQ ID NO:11;
- (c) amino acids 151 to 200 of SEQ ID NO:11; and
- (d) amino acids 121 to 215 of SEQ ID NO:11.

73. (currently amended) The polypeptide protein of claim 72 ~~which comprises~~ wherein said amino acid sequence is (a).

74. (currently amended) The polypeptide protein of claim 72 ~~which comprises~~ wherein said amino acid sequence is (b).

75. (currently amended) The polypeptide protein of claim 72 ~~which comprises~~ wherein said amino acid sequence is (c).

76. (canceled)

77. (currently amended) The polypeptide protein of claim 72 ~~which comprises~~ wherein said amino acid sequence is (d).

78. (currently amended) The polypeptide protein of claim 72, wherein said polypeptide is fused to ~~which comprises~~ a heterologous polypeptide sequence.

79. (currently amended) A composition comprising the polypeptide protein of claim 72 and a pharmaceutically acceptable carrier.

80. (currently amended) An isolated polypeptide protein produced by the method comprising:

- (a) expressing the polypeptide protein of claim 72 by a cell; and
- (b) recovering said polypeptide protein.

**Amendments to the Sequence Listing**

The Substitute Sequence Listing submitted herewith replaces all previous versions of the sequence listing. The sequence listing has been amended to show the correct amino acid sequence for BM-HABP of the present invention, as reflected in Figures 4A-B of the specification as filed. Specifically, amino acid residue 217 of SEQ ID NO:10 and SEQ ID NO:11 has been changed from an “Xaa” to a “Val.” Additionally, amino acid residue 317 has been changed from “Xaa” to “Gly.” One of skill in the art would find it obvious after viewing Figures 4A-B that the “Xaa” residues formerly shown at positions 217 and 317 in SEQ ID NO:10 and SEQ ID NO:11 should read “Val” and “Gly,” respectively. Accordingly, no new matter has been added.